Healthcare

Micro-X Limited (ASX:MX1) develops compact X-ray imaging technology for hospitals, emergency services and security screening. Its commercial mobile radiography products sit alongside development programs covering stroke diagnosis, portable computed tomography (CT) and passenger baggage inspection. The company entered October 2026 following its full-year financial …

Paragon Care Limited (ASX:PGC) supplies pharmaceuticals, medical consumables, equipment and diagnostic products to healthcare customers across Australia and other Asia-Pacific markets. Its financial year ended June 2026 followed a period of business integration after the 2024 combination of Paragon Care and Clifford Hallam Healthcare. …

Mayne Pharma Group Limited (ASX:MYX), an Australian-listed specialty pharmaceutical company with extensive US operations, enters its 2027 financial year following changes to its product distribution model and a complex period of legal proceedings. At the time of writing this article on 19 October 2026, …

Healius provides pathology and diagnostic laboratory services across Australia. Its operations include specimen collection, testing and reporting for general practitioners, specialists, hospitals and other customers. The business works across routine diagnostics and specialist areas such as genomic testing, clinical trials and veterinary pathology. Its …

Amplia Therapeutics Limited (ASX:ATX), an Australian clinical-stage biotechnology company developing oncology medicines, is progressing clinical work on narmafotinib while broadening research into combination treatments. At the time of writing this article on 19 October 2026, its shares were trading at AUD 0.082, up 2.50% …

The pivotal XanaMIA phase 2b/3 trial continued with treatment and follow-up proceeding at participating sites until the last patient visit was completed in late September. The trial remains on track to deliver topline final results in November 2026. Ahead of that, the company is …

The primary endpoints of the Phase 1 trial focus on safety. Preliminary unaudited findings from 14 patient treatment readouts showed no serious adverse events and no dose-limiting toxicities. There were eight cases of mild to moderate adverse events, such as mild headache, urinary tract …